Dynavax Technologies (NASDAQ:DVAX) Receives “Outperform” Rating from William Blair

William Blair reaffirmed their outperform rating on shares of Dynavax Technologies (NASDAQ:DVAX) in a report published on Friday morning,RTT News reports.

DVAX has been the topic of several other research reports. StockNews.com downgraded shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th. HC Wainwright reissued a “buy” rating and issued a $31.00 target price on shares of Dynavax Technologies in a research note on Friday. Finally, The Goldman Sachs Group cut shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and decreased their price target for the stock from $15.00 to $12.00 in a research note on Tuesday, February 11th.

Dynavax Technologies Stock Performance

Shares of DVAX stock opened at $13.33 on Friday. The stock has a fifty day moving average price of $12.81 and a 200 day moving average price of $11.99. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The stock has a market cap of $1.75 billion, a PE ratio of 102.55 and a beta of 1.32. Dynavax Technologies has a 1 year low of $9.74 and a 1 year high of $14.05.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.05. Dynavax Technologies had a return on equity of 3.19% and a net margin of 7.85%. The business had revenue of $72.03 million during the quarter, compared to the consensus estimate of $72.70 million. Sell-side analysts forecast that Dynavax Technologies will post 0.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dynavax Technologies

Several institutional investors and hedge funds have recently added to or reduced their stakes in DVAX. US Bancorp DE grew its holdings in shares of Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,034 shares during the period. Russell Investments Group Ltd. lifted its position in Dynavax Technologies by 96.5% during the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 1,169 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in Dynavax Technologies by 463.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 2,034 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Dynavax Technologies in the fourth quarter worth $35,000. Finally, Capital Performance Advisors LLP purchased a new position in shares of Dynavax Technologies in the 3rd quarter valued at $45,000. 96.96% of the stock is currently owned by institutional investors and hedge funds.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.